Impact of PSA testing and prostatic biopsy on cancer incidence and mortality: Comparative study between the Republic of Ireland and Northern Ireland

Cancer Causes and Control

Volumn 21, Issue 9, 2010, Pages 1523-1531

  Carsin, A E ^a   Drummond, F J ^a   Black, A ^b   Van Leeuwen, P J ^c   Sharp, L ^a   Murray, L J ^d   Connolly, D ^e   Egevad, L ^f   Boniol, M ^f   Autier, P ^f   Comber, H ^a   Gavin, A ^d  

^a NATIONAL CANCER REGISTRY IRELAND   (Ireland)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e BELFAST CITY HOSPITAL   (United Kingdom)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Incidence; Mortality; Prostate cancer; PSA tests; Trends

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CONTROLLED STUDY; GEOGRAPHIC DISTRIBUTION; HEALTH CARE SYSTEM; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TREND STUDY; UNITED KINGDOM;

AGE DISTRIBUTION; AGED; BIOPSY; HUMANS; INCIDENCE; IRELAND; MALE; MIDDLE AGED; NORTHERN IRELAND; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGISTRIES;

EID: 77956969296     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-010-9581-y     Document Type: Article

References (43)

1. R Kvåle A Auvinen HO Adami Å Klint E Hernes B Møller, et al. 2007 Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries J Natl Cancer Inst 99 24 1881 1887 10.1093/jnci/djm249 18073376
2. S Hussain D Gunnell J Donovan S McPhail F Hamdy D Neal, et al. 2008 Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004 BJU Int 101 5 547 555 10.1111/j.1464-410X.2007.07338.x 18190630
3. SE Oliver MT May D Gunnell 2001 International trends in prostate-cancer mortality in the "PSA ERA" Int J Cancer 92 6 893 898 10.1002/ijc.1260 1:STN:280:DC%2BD3M3lt1Gisg%3D%3D 11351313
4. C Bouchardy G Fioretta E Rapiti HM Verkooijen CH Rapin F Schmidlin, et al. 2008 Recent trends in prostate cancer mortality show a continuous decrease in several countries Int J Cancer 123 2 421 429 10.1002/ijc.23520 1:CAS:528:DC%2BD1cXnsF2jtrc%3D 18452171
5. W Oberaigner W Horninger H Klocker D Schönitzer W Stühlinger G Bartsch 2006 Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing Am J Epidemiol 164 4 376 384 10.1093/aje/kwj213 16829552
6. BF Hankey EJ Feuer LX Clegg RB Hayes JM Legler PC Prorok, et al. 1999 Cancer surveillance series: interpreting trends in prostate cancer-part 1: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates J Natl Cancer Inst 91 12 1017 1024 10.1093/jnci/91.12.1017 1:STN:280:DyaK1Mzgs1KgsA%3D%3D 10379964
7. EJ Feuer RM Merrill BF Hankey 1999 Cancer surveillance series: interpreting trends in prostate cancer-part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality J Natl Cancer Inst 91 12 1025 1032 10.1093/jnci/91.12.1025 1:STN:280:DyaK1Mzgs1KgsQ%3D%3D 10379965
8. R Etzioni JM Legler EJ Feuer RM Merrill KA Cronin BF Hankey 1999 Cancer surveillance series: interpreting trends in prostate cancer-part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality J Natl Cancer Inst 91 12 1033 1039 10.1093/jnci/91.12.1033 1:STN:280:DyaK1Mzgs1Kgtg%3D%3D 10379966
9. GL Andriole RL Grub III SS Buys D Chia TR Church MN Fouad, et al. 2009 Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 13 1310 1319 10.1056/NEJMoa0810696 1:CAS:528:DC%2BD1MXjs1ejsLk%3D 19297565
10. FH Schröder J Hugosson MJ Roobol TL Tammela S Ciatto V Nelen, et al. 2009 Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 13 1320 1328 10.1056/NEJMoa0810084 19297566
11. PA Shaw R Etzioni SB Zeliadt A Mariotto K Karnofski DF Penson, et al. 2004 An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States Am J Epidemiol 160 11 1059 1069 10.1093/aje/kwh336 15561985
12. SM Collin RM Martin C Metcalfe D Gunnell PC Albertsen D Neal, et al. 2008 Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study Lancet Oncol 9 5 445 452 10.1016/S1470-2045(08)70104-9 18424233
13. J Ferlay P Autier M Boniol M Heanue M Colombet P Boyle 2007 Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 3 581 592 10.1093/annonc/mdl498 1:STN:280:DC%2BD2s7hslSgtw%3D%3D 17287242
14. Drummond FJ, Sharp L, Comber H (2008) Major inter-laboratory variations in PSA testing practices: results from national surveys in Ireland in 2006 and 2007. Ir J Med Sci
15. NHS Cancer Screening Programmes. Prostate Cancer Risk Management. Available at http://www.cancerscreening.nhs.uk/prostate/index.html
16. A Gavin P McCarron RJ Middleton G Savage D Catney D O'Reilly, et al. 2004 Evidence of prostate cancer screening in a UK region BJU Int 93 6 730 734 10.1111/j.1464-410X.2003.04716.x 1:STN:280:DC%2BD2c7ls1Oltg%3D%3D 15049981
17. FK Mostofi 1975 Grading of prostatic carcinoma Cancer Chemother Rep 59 1 111 117 1:STN:280:DyaE2M7ms1amug%3D%3D 48413
18. FJ Drummond AE Carsin L Sharp H Comber 2010 Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines Ir J Med Sci 179 1 43 49 10.1007/s11845-009-0376-7 1:STN:280:DC%2BC3c%2FpvFGmsw%3D%3D 19562407
19. D Connolly A Black A Gavin PF Keane LJ Murray 2008 Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation Cancer Epidemiol Biomarkers Prev 17 2 271 278 10.1158/1055-9965. EPI-07-0515 1:CAS:528:DC%2BD1cXhslarur4%3D 18250343
20. RN Anderson AM Minino DL Hoyert HM Rosenberg 2001 Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates Natl Vital Stat Rep 49 2 1 32
21. Central Statistic Office Ireland. Available at http://www.cso.i.e
22. HJ Kim MP Fay EJ Feuer DN Midthune 2000 Permutation tests for joinpoint regression with applications to cancer rates Stat Med 19 3 335 351 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z 1:STN:280:DC%2BD3c7hsF2gug%3D%3D 10649300
23. Joinpoint regression program (version 3). National Cancer Institute. Available at http://srab.cancer.gov/joinpoint/
24. G Draisma R Boer SJ Otto IW van der Cruijsen RA Damhuis FH Schröder, et al. 2003 Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 12 868 878 10.1093/jnci/95.12.868 12813170
25. D Telesca R Etzioni R Gulati 2008 Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends Biometrics 64 1 10 19 10.1111/j.1541-0420.2007.00825.x 17501937
26. A Bill-Axelson L Holmberg M Ruutu M Haggman SO Andersson S Bratell, et al. 2005 Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 352 1977 1984 10.1056/NEJMoa043739 1:CAS:528:DC%2BD2MXjvFyrtLw%3D 15888698
27. FJ Drummond AE Carsin L Sharp S Deady DP Cronin-Fenton H Comber 2007 Treatment of prostate cancer in the real world: population-based practices, factors associated with treatment receipt and impact on survival J Epidemiol Commun Health 61 Suppl I A21
28. Gavin A, Hughes J, Ranaghan L, Fitzpatrick D. Cancer services audit 1996 & 2001, prostate. N. Ireland Cancer Registry; 2005
29. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD (2006) Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 18:CD006019
30. ES Antonarakis AL Blackford E Garrett-Mayer MA Eisenberger 2007 Survival in men with non metastatic prostate cancer treated with hormone therapy: a quantitative systematic review J Clin Oncol 25 4998 5008 10.1200/JCO.2007.11. 1559 1:CAS:528:DC%2BD2sXhtlOhtbfL 17971600
31. NicAmhlaoibh R, Mahmud S, Comber H (2004) Patterns of care and survival from cancer in Ireland 1994 to 1998. National Cancer Registry, Cork
32. RY Demers A Tiwari J Wei LK Weiss RK Severson J Montie 2001 Trends in the utilization of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality Cancer 92 9 2309 2317 10.1002/1097-0142(20011101)92:9<2309::AID-CNCR1577>3.0.CO;2-8 1:CAS:528:DC%2BD3MXotl2itLg%3D 11745285
33. JE Damber 2004 Decreasing mortality rates for prostate cancer: possible role of hormonal therapy? BJU Int 93 6 695 701 10.1111/j.1464-410X.2003.04713.x 15049974
34. J Seidenfeld DJ Samson V Hasselblad N Aronson PC Albertsen CL Bennett, et al. 2000 Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis Ann Intern Med 132 7 566 577 1:CAS:528:DC%2BD3cXis1Sjsrs%3D 10744594
35. A Docherty CP Brothwell M Symons 2007 The impact of inadequate knowledge on patient and spouse experience of prostate cancer Cancer Nurs 30 1 58 63 10.1097/00002820-200701000-00011 17235222
36. GJ Gormley D Catney JR McCall PM Reilly AT Gavin 2006 Prostate-specific antigen testing: uncovering primary care influences BJU Int 98 5 996 1000 10.1111/j.1464-410X.2006.06481.x 17034601
37. FJ Drummond A-E Carsin L Sharp H Comber 2009 Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners BMC Fam Pract 10 3 10.1186/1471-2296-10-3 19138385
38. Connolly D (2007) Long term follow-up of men with elevated prostate specific antigen levels: a population based study. MD thesis, Queen's University Belfast, Belfast
39. JM Legler EJ Feuer AL Potosky RM Merrill BS Kramer 1998 The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States Cancer Causes Control 9 5 519 527 10.1023/A:1008805718310 1:STN:280:DyaK1M7jtFCitA%3D%3D 9934717
40. DH Brewster LA Fraser V Harris RJ Black 2000 Rising incidence of prostate cancer in Scotland: increased risk or increased detection? BJU Int 85 4 463 473 10.1046/j.1464-410x.2000.00487.x 1:STN:280:DC%2BD3c7lslSjtg%3D%3D 10691826
41. Eichler K, Wilby J, Hempel S, Myers L, Kleijnen J (2005) Diagnostic value of systematic prostate biopsy methods in the investigation for prostate cancer: a systematic review. Centre for Reviews and Dissemination, York, July 2005. Report No: 29
42. MR Cooperberg JM Broering PW Kantoff PR Carroll 2007 Contemporary trends in low risk prostate cancer: risk assessment and treatment J Urol 178 S14 S19 10.1016/j.juro.2007.03.135 17644125
43. Health in the European Union. September 2007. Report No.: Special Eurobarometer 272